Clinical Trials

  • Although supraventricular tachycardia (SVT), including atrial flutter (AF), are the most common causes of intended in-utero fetal therapy, none of the medication used to date has been evaluated for their effects on the mother and her baby in a randomized controlled clinical trial (RCT). In the absence of such evidence, there is no consensus for the optimal management. The purpose of the FAST Research study is to improve the care of pregnancies affected by AF or SVT.
  • The purpose of the study is to clarify the best treatment for your babys condition by looking at how well the medicine worked to bring your babys heart rate back to normal and if you experienced any side-effects from the treatment. You are being asked to take part in a research study because your fetus has been diagnosed with a fast heart rate.
  • The population includes males and females of all ages with one or more food allergy or those who are at risk of mortality from food-induced anaphylaxis. The FARE Patient Registry is a multicenter, prospective, longitudinal, observational cohort study of patients with food allergy. The participant and the treating physician agree that he/she will complete all study required surveys and questionnaires including at minimum one food allergy exposure survey and one quality of life (QoL) survey online.
  • The population includes males and females of all ages with one or more food allergy or those who are at risk of mortality from food-induced anaphylaxis. The FARE Patient Registry is a multicenter, prospective, longitudinal, observational cohort study of patients with food allergy. The participant and the treating physician agree that he/she will complete all study required surveys and questionnaires including at minimum one food allergy exposure survey and one quality of life (QoL) survey online.
  • This study is designed to determine the role of specific genes in obesity and/or type 2 diabetes mellitus. Patients who are severely obese, and/or with an onset of type 2 diabetes at less than 25 years of age. Ideally, we would like to have families involved in this study. The ideal family is one in which NOT everyone in the family is obese or diabetic. Families in which one or neither parent is obese/diabetic, and some but not all children are obese/diabetic, are ideal.
  • The goal of this study is to better understand the genetic causes of weight gain and identify individuals who may benefit from a new treatment to help them maintain a healthy weight. Your participation will help us understand how why some people gain more weight and how individuals can stay at a healthy weight. We will ask you questions about your weight and your height to determine if you are eligible. If you are eligible, we will invite you to participate.
  • Principal Investigator

    Cindy Neunert, MD
    The purpose of this study is investigate the safety and effectiveness of eltrombopag (investigational drug) in treating children and adolescents with newly-diagnosed immune thrombocytopenia (ITP), which is a rare blood disorder.
  • Research funded by the NIH is being done to learn if an asthma medication, given along with standard asthma care, makes children less likely to have asthma attacks.
  • In this trial, we will evaluate whether partially-HLA matched allogeneic multivirus-specific VSTs, will be safe and produce anti-viral effects in immunodeficient recipients infected with one of more of the targeted viruses that are persistent despite conventional anti-viral therapy. This will be in patients who have received a hematopoietic stem cell transplant or patients with primary immunodeficiency conditions who have persistent viral infections and have not undergone HSCT.
  • The purpose of this study is to find the best dose of Palbociclib that can be given safely with chemotherapy in children and young adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) which has come back or has not responded to standard therapy. Palbociclib is considered experimental because it has not been approved by the United States (US) Food and Drug Administration (FDA) for treating children with Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). Palbociclib works by targeting proteins that are necessary for cell growth.

Pages